A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Spondylarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 May 2017 Planned End Date changed from 1 Nov 2019 to 19 Jun 2020.
- 03 May 2017 Planned primary completion date changed from 1 Nov 2019 to 26 Apr 2019.
- 17 May 2016 Status changed from not yet recruiting to recruiting.